

NYUES4	48	Christoph Hansis, MD, PhD	New York University School of Medicine	03/29/2010
(see details)				
NYUES5	49	Christoph Hansis, MD, PhD	New York University School of Medicine	03/29/2010
(see details)				
NYUES6	50	Christoph Hansis, MD, PhD	New York University School of Medicine	03/29/2010
(see details)				
NYUES7	51	Christoph Hansis, MD, PhD	New York University School of Medicine	03/29/2010
(see details)				
MFS5; disease-specific mutation	52	Eric Chiao	Stanford University	04/27/2010
(see details)				
HUES 48	53	HSCI iPS Core	Harvard University	04/27/2010
(see details)				
HUES 49	54	HSCI iPS Core	Harvard University	04/27/2010
(see details)				
HUES 53	55	HSCI iPS Core	Harvard University	04/27/2010
(see details)				
HUES 65	56	HSCI iPS Core	Harvard University	04/27/2010
(see details)				
HUES 66	57	HSCI iPS Core	Harvard University	04/27/2010
(see details)				
UCLA 1	58	Steven Peckman	University of California, Los Angeles	04/27/2010
(see details)				
UCLA 2	59	Steven Peckman	University of California, Los Angeles	04/27/2010
(see details)				
UCLA 3	60	Steven Peckman	University of California, Los Angeles	04/27/2010
(see details)				
WA07 (H7)	61	WiCell Research Institute	WiCell Research Institute	04/27/2010
(see details)				
WA09 (H9)	62	WiCell Research Institute	WiCell Research Institute	04/27/2010
(see details)				
WA13 (H13)	63	WiCell Research Institute	WiCell Research Institute	04/27/2010
(see details)				
WA14 (H14)	64	WiCell Research Institute	WiCell Research Institute	04/27/2010
(see details)				
HUES 62	65	HSCI iPS Core	Harvard University	06/03/2010
(see details)				
HUES 63	66	HSCI iPS Core	Harvard University	06/03/2010
(see details)				
HUES 64	67	HSCI iPS Core	Harvard University	06/03/2010
(see details)				
CT1	68	University of Connecticut Stem Cell Core	UNIVERSITY OF CONNECTICUT SCH OF MED/DNT	06/21/2010
(see details)				
CT2	69	University of Connecticut Stem Cell Core	UNIVERSITY OF CONNECTICUT SCH OF MED/DNT	06/21/2010
(see details)				

CT3	70	University of Connecticut Stem Cell Core	UNIVERSITY OF CONNECTICUT SCH OF MED/DNT	06/21/2010
(see details)				
CT4	71	University of Connecticut Stem Cell Core	UNIVERSITY OF CONNECTICUT SCH OF MED/DNT	06/21/2010
(see details)				
MA135	72	Advanced Cell Technology, Inc.	Advanced Cell Technology, Inc.	06/21/2010
(see details)				
Endeavour-2	73	Kuldip Sidhu	Stem Cell Laboratory, Faculty of medicine, University of New South Wales	06/21/2010
(see details)				
WIBR1	74	Whitehead Institute for Biomedical Research/Maya Mitalipova	Whitehead Institute for Biomedical Research	06/21/2010
(see details)				
WIBR2	75	Whitehead Institute for Biomedical Research/Maya Mitalipova	Whitehead Institute for Biomedical Research	06/21/2010
(see details)				
HUES 45	76	HSCI iPS Core	Harvard University	09/28/2010
(see details)				
Shef 3	77	Centre for Stem Cell Biology	University of Sheffield	11/17/2010
(see details)				
Shef 6	78	Centre for Stem Cell Biology	University of Sheffield	11/17/2010
(see details)				
WIBR3	79	Whitehead Institute for Biomedical Research/Maya Mitalipova	Whitehead Institute for Biomedical Research	11/17/2010
(see details)				
WIBR4	80	Whitehead Institute for Biomedical Research/Maya Mitalipova	Whitehead Institute for Biomedical Research	11/17/2010
(see details)				
WIBR5	81	Whitehead Institute for Biomedical Research/Maya Mitalipova	Whitehead Institute for Biomedical Research	11/17/2010
(see details)				

WIBR6	82	Whitehead Institute for Biomedical Research/Maya Mitalipova	Whitehead Institute for Biomedical Research	11/17/2010
(see details)				
BJNhem19	83	Jawaharlal Nehru Centre for Advanced Scientific	Jawaharlal Nehru Centre for Advanced Scientific Research	12/17/2010
(see details)				
BJNhem20	84	Jawaharlal Nehru Centre for Advanced Scientific	Jawaharlal Nehru Centre for Advanced Scientific Research	12/17/2010
(see details)				
SA001	85	Cellartis AB	Cellartis AB	12/17/2010
(see details)				
SA002; abnormal karyotype	86	Cellartis AB	Cellartis AB	12/17/2010
(see details)				
UCLA 4	87	Steven Peckman	University of California Los Angeles	02/03/2011
(see details)				
UCLA 5	88	Steven Peckman	University of California Los Angeles	02/03/2011
(see details)				
UCLA 6	89	Steven Peckman	University of California Los Angeles	02/03/2011
(see details)				
HUES PGD 13; disease-specific mutation	90	Eggan Lab	Harvard University	03/15/2011
(see details)				
HUES PGD 3; disease-specific mutation	91	Eggan Lab	Harvard University	03/15/2011
(see details)				
ESI-014	92	BioTime, Inc.	BioTime, Inc.	06/02/2011
(see details)				
ESI-017	93	BioTime, Inc.	BioTime, Inc.	06/02/2011
(see details)				
HUES PGD 11; disease-specific mutation	94	Eggan Lab	Harvard University	06/07/2011
(see details)				
HUES PGD 12; disease-specific mutation	95	Eggan Lab	Harvard University	06/07/2011
(see details)				
WA15	96	WiCell Research Institute	WiCell Research Institute	06/09/2011
(see details)				
WA16; disease-specific mutation/abnormal karyotype	97	WiCell Research Institute	WiCell Research Institute	06/09/2011
(see details)				
WA17	98	WiCell Research Institute	WiCell Research Institute	06/09/2011
(see details)				

WA18	99	WiCell Research Institute	WiCell Research Institute	06/09/2011
(see details)				
WA19	100	WiCell Research Institute	WiCell Research Institute	06/09/2011
(see details)				
WA20	101	WiCell Research Institute	WiCell Research Institute	06/09/2011
(see details)				
WA21	102	WiCell Research Institute	WiCell Research Institute	06/09/2011
(see details)				
WA22	103	WiCell Research Institute	WiCell Research Institute	06/09/2011
(see details)				
WA23	104	WiCell Research Institute	WiCell Research Institute	06/09/2011
(see details)				
WA24	105	WiCell Research Institute	WiCell Research Institute	06/09/2011
(see details)				
CSES2	106	Juan Carlos Biancotti	Cedars-Sinai Medical Center	06/10/2011
(see details)				
CSES4	107	Juan Carlos Biancotti	Cedars-Sinai Medical Center	06/10/2011
(see details)				
CSES7	108	Juan Carlos Biancotti	Cedars-Sinai Medical Center	06/10/2011
(see details)				
CSES8; abnormal karyotype	109	Juan Carlos Biancotti	Cedars-Sinai Medical Center	06/10/2011
(see details)				
CSES11; abnormal karyotype	110	Juan Carlos Biancotti	Cedars-Sinai Medical Center	06/10/2011
(see details)				
CSES12; abnormal karyotype	111	Juan Carlos Biancotti	Cedars-Sinai Medical Center	06/10/2011
(see details)				
CSES13; abnormal karyotype	112	Juan Carlos Biancotti	Cedars-Sinai Medical Center	06/10/2011
(see details)				
CSES14; abnormal karyotype	113	Juan Carlos Biancotti	Cedars-Sinai Medical Center	06/10/2011
(see details)				
CSES15	114	Juan Carlos Biancotti	Cedars-Sinai Medical Center	06/10/2011
(see details)				
CSES17	115	Juan Carlos Biancotti	Cedars-Sinai Medical Center	06/10/2011
(see details)				
CSES19	116	Juan Carlos Biancotti	Cedars-Sinai Medical Center	06/10/2011
(see details)				
CSES20; abnormal karyotype	117	Juan Carlos Biancotti	Cedars-Sinai Medical Center	06/10/2011
(see details)				
CSES21; abnormal karyotype	118	Juan Carlos Biancotti	Cedars-Sinai Medical Center	06/10/2011
(see details)				
CSES22; abnormal karyotype	119	Juan Carlos Biancotti	Cedars-Sinai Medical Center	06/10/2011
(see details)				
CSES23; abnormal karyotype	120	Juan Carlos Biancotti	Cedars-Sinai Medical Center	06/10/2011
(see details)				

CSES24; abnormal karyotype	121	Juan Carlos Biancotti	Cedars-Sinai Medical Center	06/10/2011
(see details)				
CSES25	122	Juan Carlos Biancotti	Cedars-Sinai Medical Center	06/10/2011
(see details)				
HAD-C 100	123	Benjamin E. Reubinoff	Hadassah Hebrew University Medical Center	06/16/2011
(see details)				
HAD-C 102	124	Benjamin E. Reubinoff	Hadassah Hebrew University Medical Center	06/16/2011
(see details)				
HAD-C 106	125	Benjamin E. Reubinoff	Hadassah Hebrew University Medical Center	06/16/2011
(see details)				
RNJ19; disease-specific mutation	126	Reprogenetics, LLC	Reprogenetics, LLC	06/16/2011
(see details)				
RNJ20; disease-specific mutation	127	Reprogenetics, LLC	Reprogenetics, LLC	06/16/2011
(see details)				
RNJ18; disease-specific mutation	128	Reprogenetics, LLC	Reprogenetics, LLC	06/16/2011
(see details)				
ESI-035	129	BioTime, Inc.	BioTime, Inc.	08/18/2011
(see details)				
ESI-049	130	BioTime, Inc.	BioTime, Inc.	08/18/2011
(see details)				
ESI-051	131	BioTime, Inc.	BioTime, Inc.	08/18/2011
(see details)				
ESI-053	132	BioTime, Inc.	BioTime, Inc.	08/18/2011
(see details)				
CSES5; abnormal karyotype	133	Juan Carlos Biancotti	Cedars-Sinai Medical Center	09/27/2011
(see details)				
CSES6; abnormal karyotype	134	Juan Carlos Biancotti	Cedars-Sinai Medical Center	09/27/2011
(see details)				
CSES18	135	Juan Carlos Biancotti	Cedars-Sinai Medical Center	09/27/2011
(see details)				
HUES PGD 14; disease-specific mutation	136	Eggan Lab	Harvard University	10/11/2011
(see details)				
CA1	137	Andras Nagy	Mt Sinai Hosp-Samuel Lunenfeld Research Institute	12/12/2011
(see details)				
CA2	138	Andras Nagy	Mt Sinai Hosp-Samuel Lunenfeld Research Institute	12/12/2011
(see details)				
MEL-1	139	StemCore, Stem Cells Ltd	University of Queensland	12/22/2011
(see details)				
MEL-2	140	StemCore, Stem Cells Ltd	University of Queensland	12/22/2011
(see details)				

MEL-3	141	StemCore, Stem Cells Ltd	University of Queensland	12/22/2011
(see details)				
MEL-4	142	StemCore, Stem Cells Ltd	University of Queensland	12/22/2011
(see details)				
UCLA 7; disease-specific mutation/abnormal karyotype	143	Steven Peckman	University of California, Los Angeles	01/12/2012
(see details)				
UCLA 8	144	Steven Peckman	University of California, Los Angeles	01/12/2012
(see details)				
UCLA 9	145	Steven Peckman	University of California, Los Angeles	01/12/2012
(see details)				
UCLA 10	146	Steven Peckman	University of California, Los Angeles	01/12/2012
(see details)				
UM4-6	147	Gary D. Smith, University of Michigan	University of Michigan	02/02/2012
(see details)				
HUES PGD 1; disease-specific mutation	148	Eggen Lab	Harvard University	02/24/2012
(see details)				
HUES PGD 15; possible disease-specific mutation	149	Eggen Lab	Harvard University	02/24/2012
(see details)				
HUES PGD 16; disease-specific mutation	150	Eggen Lab	Harvard University	02/24/2012
(see details)				
GENEA002	151	GENEA	GENEA	03/20/2012
(see details)				
GENEA048; abnormal karyotype	152	GENEA	GENEA	03/20/2012
(see details)				
UM11-1PGD; disease-specific mutation	153	Gary D. Smith, University of Michigan	University of Michigan	04/12/2012
(see details)				

UM9-1PGD; disease-specific mutation	154	Gary D. Smith, University of Michigan	University of Michigan	05/14/2012
(see details)				
UM38-2 PGD; disease-specific mutation	155	Gary D. Smith, University of Michigan	University of Michigan	05/14/2012
(see details)				
Elf1	156		University of Washington	05/15/2012
(see details)				
HUES 42	157	HSCI iPS Core	Harvard University	05/31/2012
(see details)				
HUES 44	158	HSCI iPS Core	Harvard University	05/31/2012
(see details)				
NMR-1	159	Rick A. Wetsel, Ph.D.	University of Texas Hlth Sci Ctr Houston	05/31/2012
(see details)				
UM17-1 PGD; disease-specific mutation	160	Gary D. Smith/University of Michigan	University of Michigan	05/31/2012
(see details)				
UM15-4 PGD; disease-specific mutation	161	University of Michigan, Gary D. Smith	University of Michigan	05/31/2012
(see details)				
UM14-1	162	Gary D. Smith/University of Michigan	University of Michigan	05/31/2012
(see details)				
UM14-2	163	Gary D. Smith/University of Michigan	University of Michigan	05/31/2012
(see details)				
UM29-2 PGD; disease-specific mutation	164	Gary D. Smith/University of Michigan	University of Michigan	06/18/2012
(see details)				
UM29-3 PGD; disease-specific mutation	165	Gary D. Smith/University of Michigan	University of Michigan	06/18/2012
(see details)				
GENEA017; disease-specific mutation	166	GENEA	GENEA	06/20/2012
(see details)				
GENEA041; disease-specific mutation	167	GENEA	GENEA	06/20/2012
(see details)				
GENEA068; disease-specific mutation	168	GENEA	GENEA	06/20/2012
(see details)				
GENEA018; disease-specific mutation	169	GENEA	GENEA	06/20/2012
(see details)				
GENEA024; disease-specific mutation	170	GENEA	GENEA	06/20/2012
(see details)				
GENEA040; disease-specific mutation	171	GENEA	GENEA	06/20/2012
(see details)				

GENEA060; disease-specific mutation	172	GENEA	GENEA	06/20/2012
(see details)				
GENEA061; disease-specific mutation	173	GENEA	GENEA	06/20/2012
(see details)				
GENEA064; disease-specific mutation	174	GENEA	GENEA	06/20/2012
(see details)				
GENEA059; disease-specific mutation	175	GENEA	GENEA	07/09/2012
(see details)				
HUES 68	176	HSCI iPS Core	Harvard University	07/09/2012
(see details)				
HUES 70	177	HSCI iPS Core	Harvard University	07/09/2012
(see details)				
HUES 69	178	HSCI iPS Core	Harvard University	08/07/2012
(see details)				
HUES PGD 10	179	Eggan Lab	Harvard University	09/24/2012
(see details)				
GENEA046; disease-specific mutation	180	GENEA	GENEA	10/05/2012
(see details)				
GENEA069; disease-specific mutation	181	GENEA	GENEA	10/05/2012
(see details)				
GENEA070; disease-specific mutation	182	GENEA	GENEA	10/05/2012
(see details)				
GENEA049; disease-specific mutation	183	GENEA	GENEA	11/02/2012
(see details)				
GENEA050; disease-specific mutation	184	GENEA	GENEA	11/02/2012
(see details)				
UCLA 11	185	Steven Peckman	University of California, Los Angeles	11/20/2012
(see details)				
UCLA 12	186	Steven Peckman	University of California, Los Angeles	11/20/2012
(see details)				
GENEA062; disease-specific mutation	187	GENEA	GENEA	12/14/2012
(see details)				
GENEA063; disease-specific mutation	188	GENEA	GENEA	12/14/2012
(see details)				
GENEA066; disease-specific mutation	189	GENEA	GENEA	12/14/2012
(see details)				

GENEA067; disease-specific mutation	190	GENEA	GENEA	12/14/2012
(see details)				
GENEA071; disease-specific mutation	191	GENEA	GENEA	12/14/2012
(see details)				
GENEA072; disease-specific mutation	192	GENEA	GENEA	12/14/2012
(see details)				
GENEA073; disease-specific mutation	193	GENEA	GENEA	12/14/2012
(see details)				
GENEA074; disease-specific mutation	194	GENEA	GENEA	12/14/2012
(see details)				
HUES PGD 2; possible disease-specific mutation	195	Eggan Lab	Harvard University	12/14/2012
(see details)				
WA25	196	WiCell Research Institute	WiCell Research Institute	12/14/2012
(see details)				
WA26	197	WiCell Research Institute	WiCell Research Institute	12/14/2012
(see details)				
WA27	198	WiCell Research Institute	WiCell Research Institute	12/14/2012
(see details)				
GENEA058; Disease-specific mutation	199	GENEA	GENEA	01/08/2013
(see details)				
GENEA065; Disease-specific mutation	200	GENEA	GENEA	01/08/2013
(see details)				
HS346	201	Karolinska Institute	Karolinska Institute	03/18/2013
(see details)				
HS401	202	Karolinska Institute	Karolinska Institute	03/18/2013
(see details)				
HS420	203	Karolinska Institute	Karolinska Institute	03/18/2013
(see details)				
I3 (TE03)	204	Technion R&D foundation	Technion R&D Foundation	03/18/2013
(see details)				
I4 (TE04)	205	Technion R&D foundation	Technion R&D Foundation	03/18/2013
(see details)				
I6 (TE06)	206	Technion R&D foundation	Technion R&D Foundation	03/18/2013
(see details)				
HS799; disease-specific mutation	207	Karolinska Institute	Karolinska Institute	03/18/2013
(see details)				
UM57-1 PGD; disease-specific mutation	208	Gary D. Smith/University of Michigan	University of Michigan	03/26/2013
(see details)				
UM22-2	209	Gary D. Smith/University of Michigan	University of Michigan	03/26/2013
(see details)				
CR-4	210	Rick A. Wetsel, Ph.D.	University of Texas Hlth Sci Ctr at Houston	05/29/2013
(see details)				

WCMC-37; disease-specific mutation	211	Weill Cornell Medical College- Nikica Zaninovic, PhD and Zev Rosenwaks, MD	Joan & Sanford I. Weill Medical College of Cornell University	06/27/2013
(see details)				
KCL011	212	Dusko Ilic, King's College London	King's College London	09/19/2013
(see details)				
KCL012; disease-specific mutation	213	Dusko Ilic, King's College London	King's College London	09/19/2013
(see details)				
KCL013; disease-specific mutation	214	Dusko Ilic, King's College London	King's College London	09/19/2013
(see details)				
KCL015; disease-specific mutation	215	Dusko Ilic, King's College London	King's College London	09/19/2013
(see details)				
KCL016; disease-specific mutation	216	Dusko Ilic, King's College London	King's College London	09/19/2013
(see details)				
KCL017; disease-specific mutation	217	Dusko Ilic, King's College London	King's College London	09/19/2013
(see details)				
KCL018; disease-specific mutation	218	Dusko Ilic, King's College London	King's College London	09/19/2013
(see details)				
KCL021; disease-specific mutation	219	Dusko Ilic, King's College London	King's College London	09/19/2013
(see details)				
KCL024; disease-specific mutation	220	Dusko Ilic, King's College London	King's College London	09/19/2013
(see details)				
KCL025; disease-specific mutation	221	Dusko Ilic, King's College London	King's College London	09/19/2013
(see details)				
KCL026; disease-specific mutation	222	Dusko Ilic, King's College London	King's College London	09/19/2013
(see details)				
KCL027; disease-specific mutation	223	Dusko Ilic, King's College London	King's College London	09/19/2013
(see details)				
KCL028; disease-specific mutation	224	Dusko Ilic, King's College London	King's College London	09/19/2013
(see details)				
KCL029; disease-specific mutation	225	Dusko Ilic, King's College London	King's College London	09/19/2013
(see details)				
KCL030; disease-specific mutation	226	Dusko Ilic, King's College London	King's College London	09/19/2013
(see details)				
KCL035; disease-specific mutation	227	Dusko Ilic, King's College London	King's College London	09/19/2013
(see details)				
GENEA015	228	Genea Biocell	Genea	09/30/2013
(see details)				
GENEA016	229	Genea Biocell	Genea	09/30/2013
(see details)				